BIOMAT Database Logo BIOMAT Database Logo

Adjuvant interferon alfa for melanoma. 2010

Kenneth S Wilson, and Andrew Attwell

UI MeSH Term Description Entries

Related Publications

Kenneth S Wilson, and Andrew Attwell
Adjuvant interferon alfa-2b for high-risk melanoma.
June 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Kenneth S Wilson, and Andrew Attwell
Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
January 2009, Archives of dermatology,
Kenneth S Wilson, and Andrew Attwell
Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?
May 2009, Current oncology (Toronto, Ont.),
Kenneth S Wilson, and Andrew Attwell
Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.
April 1999, Lancet (London, England),
Kenneth S Wilson, and Andrew Attwell
Severe Raynaud syndrome induced by adjuvant interferon alfa in metastatic melanoma.
August 2010, Current oncology (Toronto, Ont.),
Kenneth S Wilson, and Andrew Attwell
[Adjuvant therapy with recombinant interferon alfa-2a in metastasized malignant melanoma].
May 1989, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Kenneth S Wilson, and Andrew Attwell
Interferon alfa-2a for melanoma metastases.
March 2002, Lancet (London, England),
Kenneth S Wilson, and Andrew Attwell
Adjuvant interferon for melanoma.
August 2002, Annals of oncology : official journal of the European Society for Medical Oncology,
Kenneth S Wilson, and Andrew Attwell
PET positive generalized lymphadenopathy and splenomegaly following interferon-alfa-2b adjuvant therapy for melanoma.
October 2007, Clinical nuclear medicine,
Kenneth S Wilson, and Andrew Attwell
Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
July 2008, Lancet (London, England),
Copied contents to your clipboard!